News
Dako and Quintiles form alliance to speed development of personalized medicine
Dako, a Danish-based world leader in tissue-based cancer diagnostics, and Quintiles, the world’s leading bio pharmaceutical services companies, announced a strategic alliance to advance personalized medicine by collaborating on the co-development of targeted therapies and companion diagnostics. ...
News
Pfizer’s Lyrica® (Pregabalin) Capsules CV Receives Approval for Treatment of Peripheral Neuropathic Pain In Japan
Pfizer Inc announced today that the Japanese Ministry of Health, Labour and Welfare approved Lyrica® (pregabalin) capsules for the treatment of peripheral neuropathic pain. This follows the recent approval in Japan of Lyrica for the treatment...
News
PRADAX gains approval in Canada for stroke prevention in atrial fibrillation
Health Canada, the Canadian health authority, has approved PRADAX™ (dabigatran etexilate), 1 Boehringer Ingelheim’s novel, oral direct thrombin inhibitor 2 for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF) in whom anticoagulation is appropriate,...
News
Significant Milestone for Tengion Clinical Program Currently Enrolling Bladder Cancer Patients
Tengion, Inc., a leader in regenerative medicine, announced that surgeons at the University of Chicago have implanted its Neo-Urinary Conduit(TM) in the first patient as part of the ongoing clinical trial evaluating the Company's lead product candidate in bladder...
News
AstraZeneca initiates phase IIB study for AZD9773 (CytoFab) as a treatment for severe sepsis
AstraZeneca announced that it has commenced dosing patients in a global Phase IIb study to compare the efficacy and safety of AZD9773 (CytoFab) with placebo in adult patients with severe sepsis and/or septic shock receiving best supportive care. ...
News
Cipla launches the world’s first generic Pirfenidone in India
Cipla, among the world's leading generic pharmaceutical companies has introduced Pirfenidone in India; under the brand name Pirfenex, for the treatment of IPF. A chronic progressive form of lung disease, IPF has average survival rates as low as 3-5...
News
Sandoz announces launch of piperacillin and tazobactam for injection, a generic version of Zosyn
Sandoz anounced the launch of piperacillin and tazobactam for injection, a generic equivalent of Zosyn®, in the US. Piperacillin and tazobactam for injection is an antibacterial treatment indicated for use in adults with certain types of moderate to severe...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
